Observational Immunomonitoring Study of NK/T and Myelocites Status in Cancer Patients and Controls
CD247 Known also as the zeta chain is important for relaying T-cell induced signal
transduction.
Interestingly studies by Baniash and others have demonstrated that this chain is down
regulated in states of chronic inflammation and cancer in peripheral blood T cells and also
in NK cells However there has not been a prospective study of this marker in cancer and
control patients such a study will reveal not only the levels of CD247 in immune cells of
cancer patients compared to controls but may reveal the effect of anticancer therapies on
CD247 in cancer patients such a study may contribute significantly to our ability to monitor
systemic immune system characteristics in cancer patients and help in any further studies of
immunomodulation such as vaccination schemes in such patients
Observational
Observational Model: Cohort, Time Perspective: Prospective
changes in immune markers mainly cd247-zeta chain - levels in cancer patients undergoing therapy
Hopefully by this time the investigators will be able to see if there are lower zeta chain intracellular expression levels in cancer patients and whether response to therapy enhances recovery of zeta chain
4-2013 24 month
No
Hovav Nechushtan, MD PhD
Principal Investigator
Oncology Dept Hadassah Hebrew University Medical Center
Israel: Ministry of Health
zeta-im-1
NCT01312701
March 2011
December 2013
Name | Location |
---|